Adjunctive linezolid versus clindamycin for toxin inhibition in Î²-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation.|https://dx.doi.org/10.1016/S1473-3099(24)00507-3
